Ocala

Running trials

• Recruiting

  A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

  NCT06528314· Phase 3· Source

• Recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  NCT06215716· Phase 3· Source

• Active, not recruiting

  A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT06161571· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

  NCT05039450· Phase 2· Source

• Completed

  A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT04767529· Phase 2· Source